uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT02964988
Last Updated: 2019-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
17 participants
INTERVENTIONAL
2017-01-31
2019-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
NCT03307460
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
NCT04928820
C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
NCT02715583
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
NCT02437539
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
NCT02805608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
uPAR PET/CT
Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
Injection of PET tracer 68Ga-NOTA-AE105
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
PET/CT
Whole body PET/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Injection of PET tracer 68Ga-NOTA-AE105
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
PET/CT
Whole body PET/CT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Approved to receive Radium-223 therapy
* Written and oral consent
Exclusion Criteria
* Other known malignant disease
* Known allergy towards IMP
* Severe claustrophobia
* If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marie Øbro Fosbøl
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie Fosboel, MD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-002184-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AK-2016-PC-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.